AME · Q2 2025 Earnings
BullishAmetek
Reported July 31, 2025
30-second summary
Ametek delivered record Q2 sales of $1.78B (+2.5% YoY) with organic growth flat — the print is entirely about margin execution and M&A optionality, not demand. Operating margin held at 26% (+20bps YoY) while core margins expanded 90bps to 26.7%, and management raised the FY EPS floor to $7.06–$7.20 while folding in the $920M FARO acquisition. The $100M tariff headwind flagged last quarter is now characterized as fully offset through pricing, localization, and supply chain action — a notable shift from "mitigation plan" to "executing the playbook."
Headline numbers
EPS
Q2 FY2025
$1.78
Revenue
Q2 FY2025
$1.78B
+2.5% YoY
Gross margin
Q2 FY2025
35.8%
Operating margin
Q2 FY2025
26.0%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $1.78B | +2.5% |
| EPS | $1.78 | — |
| Gross margin | 35.8% | — |
| Operating margin | 26.0% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Electronic Instruments Group (EIG) | $1.16B | +1.0% |
| Electromechanical Group (EMG) | $0.619B | +6.0% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Operating Income | $461.6 million |
| EIG Operating Margin | 29.7% |
| EMG Operating Margin | 23.3% |
| EMG Operating Income Growth | +17% YoY |
| EBITDA | Record level |
Management tone
Four shifts stand out in a quarter where the headline organic number was flat.
From organic growth as the narrative to margins and absolute records as the narrative. With organic sales flat and acquisitions adding 1.5 points, management led with record sales, record EBITDA, and 90bps of core margin expansion rather than defending the volume line. Kevin Coleman: "Our ability to deliver strong operating performance is notable given the challenging macro environment and is a testament to the quality of our differentiated businesses." This reframes a soft top-line print as evidence of mix and pricing power rather than a demand problem to apologize for.
From tariffs as an emerging risk to tariffs as already managed. Last quarter Ametek flagged a $100M tariff headwind and a $70M China revenue exposure. In prepared remarks this quarter, Zapico framed the response as "we have a proven playbook…and we are making outstanding progress" — a step up from last quarter's "well-defined mitigation plans" language. In Q&A with Jamie Cook, management went further, saying the $100M "is not a negative headwind" going forward, with direct costs offset by pricing, supply chain adjustments, and localization, and a "good portion" of the China exposure shipping in Q2 when the market reopened. That is a meaningful confidence step-up.
From selective M&A to structural, aggressive deployment. Management closed FARO for $920M post-quarter and went out of their way to size the remaining war chest: $2B of existing cash and credit, $4.5–5B if levered to 2.5x. "Strategic acquisitions are a core component of the Ametek growth model, and we are committed to deploying our strong cash flow to expand our portfolio." The Zygo comparison for FARO (9% sales CAGR, 5x EBITDA growth, 2.5x margin expansion over 10 years) is a deliberate signal that the FARO deal is being underwritten to a known template, not as a one-off.
From macro as headwind to macro as competitive proof point. Hedging language is present ("situation remains fluid," "we anticipate remaining active") but it is appended to confident statements rather than qualifying them. The overall posture is more forward-deployed than typical for a diversified industrial facing trade uncertainty.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Jeffrey Sprague · Vertical Research
Integration plan for FARO acquisition, expected synergies beyond typical Ametek playbook, and why minimal 2025 EPS benefit despite higher margins coming in
FARO will contribute a couple pennies in 2025 (partial Q3-Q4). Mid-teens cost synergies expected. EBITDA margins to expand from ~15% to ~30% in three years through integration into Ametek infrastructure. Compared FARO to successful Zygo acquisition: Zygo achieved 9% sales CAGR, 5x EBITDA growth, 2.5x margin improvement over 10 years. FARO has similar unfocused business model with significant talent and capability to unlock.
Jamie Cook · Truist
Conservatism level in 2025 guidance, understanding puts and takes relative to $100M tariff cost and $70M China exposure flagged last quarter; EMG margin expansion outlook
Couple cents from FARO built into guidance. Good portion of $70M China tariff exposure shipped in Q2 when market reopened. $100M negative tariff headwind is 'not a negative headwind' going forward—direct tariff costs being offset by pricing, supply chain adjustments, localization, and cost reductions. Some conservatism in Q3 near-term guide given changing dynamics, but confident overall. EMG margins expanded 260bps core basis; both EIG and EMG had strong pricing and productivity.
Matt Somerville · DA Davidson
Paragon and automation business profitability performance, D-stock inventory dynamics, right forward organic growth algorithm, M&A pipeline post-FARO, deal size/multiples environment
Paragon had excellent quarter with robust orders, strong sales, 30%+ EBITDA margins now in line with Ametek average, meaningful margin runway ahead. D-stock is complete. Automation business similarly inflecting up with mid-single-digit organic growth expected for full year and potential upside if orders continue. M&A pipeline remains strong; deployed $1B and acquired $400M revenue in 2024. With $2B cash and credit, levered to 2.5x equals $4.5-5B spending capacity. Highly focused on differentiation through M&A combined with operational excellence.
Andrew Obin · Bank of America
Pull forward demand in China on metrology given tariff uncertainty; whether short-cycle industrial has bottomed and organic growth expectations improving
China down low single digits for quarter, no meaningful pull forward of metrology demand. Delays driven by uncertainty and funding delays for projects, not demand destruction. Strong underlying demand persists. Other segments showing inflection: A&D strength, power accelerating on grid spending, automation/Paragon inflecting upward with strong orders. Process business dealing with sluggish markets but not weakening incrementally; pipeline solid with reshoring quotations. Overall positive across three of four market segments.
Nigel Coe · Wolf Research
EIG book-to-bill breakdown between A&D and other units; research/academia funding headwinds in Gatan and process business, sizing exposure and duration
A&D book-to-bill above 1.0 (backlog business with 3-6-9 months to 1-year lead times). Research market represents ~10% of Ametek; research and semiconductor markets were headwinds in quarter. U.S. research funding seeing some project deferrals and reduced spend on projects, though projects still desired. Research market 25-30% U.S., remainder international. China research exposure also impacted. Expect headwinds to continue through Q3; Q4 timing uncertain. Food, med tech, A&D, and automation verticals positive.
What to watch into next quarter
FARO integration print: First full quarter of contribution in Q4. Watch for EBITDA margin trajectory off the ~15% base — Zygo precedent implies visible improvement within 12 months.
Tariff offset durability: Management has effectively committed to a fully neutralized $100M tariff impact. Any erosion of that offset in Q3 (price/cost mismatch, China demand softness) would directly hit the FY EPS guide.
Organic growth inflection: Flat organic in Q2 with management pointing to A&D, power, and automation/Paragon as inflecting positive. Watch whether Q3 organic prints positive low-single-digit as guided, or whether research and semiconductor drag keeps it at zero.
Research/academia headwind duration: Management explicitly said headwinds persist through Q3 with Q4 uncertain. Continued funding deferrals from a ~10% revenue segment would dent EIG margins.
M&A cadence: Management telegraphed $4.5–5B of capacity and a "robust" pipeline. Pace of further deployment after the $920M FARO close will signal whether this is a multi-deal year.
Sources
- AME Q2 2025 press release / 8-K Exhibit 99.1, filed 2025-07-31 — https://www.sec.gov/Archives/edgar/data/1037868/000103786825000055/ametek8kexhibit99173125.htm
- AME Q2 2025 earnings call commentary (prepared remarks and Q&A excerpts as supplied)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.